Financial guidance 2021
|
in € million |
Guidance 2021 |
Results 2020 |
|---|---|---|
| Group Revenues | 150 to 200* | 327.7 |
| Operating Expenses | 355 to 385** | 309.7 |
| Share of R&D in Operating Expenses (in %) | 45 to 50% | 45.7% |
*This forecast on Group revenues includes the announced € 16 million milestone payments from GSK, but excludes other potential significant milestones from development partners and/or licensing partnerships. This revenue guidance is subject to a number of uncertainties including the potential for variability from the first full year of the Monjuvi product launch, the limited visibility that MorphoSys has on the Tremfya royalty stream as well as the ongoing COVID-19 pandemic and the impact on our as well as our partner’s business operations.
**Operating expenses, inclusive of Incyte’s share of Monjuvi selling costs.
